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The relation between plasma norepinephrine levels and
the occurrence of ventricular tachycardia during exer-
cise testing was prospectively evaluated in 17 patients.
Ten patients had reproducible ventricular tachycardia
exclusively during exercise or recovery, or both; 7 pa-
tients had ventricular tachycardia only during ambu-
latory electrocardiographic monitoring. The two groups
did not differ in age, exercise duration, left ventricular
ejection fraction at rest, heart rate throughout the ex-
ercise protocol, rest QTc interval, change in QTc inter-
val during exercise, the presence of coronary artery dis-
ease or exercise-related myocardial ischemia.
Furthermore, there was no difference between groups
in plasma norepinephrine levelsat rest, peak exerciseor
in the recovery period. Myocardial ischemia was de-
tectable by thaJIium perfusion scan in only 2 of the 10
patients with exercise-induced ventricular tachycardia.
The occurrence of ventricular ectopic activity and ventric-
ular tachycardia during exercise testing has been the subject
of considerable investigation over the last decade. Terms
such as exercise-induced ventricular ectopic activity/ven-
tricular tachycardia or catecholamine-induced ventricular
ectopic activity/ventricular tachycardia have been used to
describe this phenomenon; however, these are often variably
interpreted.
In one sense the term exercise-induced ventricular tachy-
cardia has been used to describe an uncommon, variably
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The 10 patients with exercise-induced ventricular
tachycardia underwent repeat exercise testing immedi-
ately after maximal intravenous beta-adrenergic block-
ade with propranolol. Although they had no change in
exercise duration, ventricular tachycardia did not occur
in 9 of these 10 patients. Plasma norepinephrine levels
were significantlydecreased compared with levelsbefore
beta-adrenergic blockade (p < 0.0002).
Thus, plasma norepinephrine levels do not distin-
guish patients with reproducible exercise-induced ven-
tricular tachycardia from otherwise comparable pa-
tients. Propranolol is highly effective in abolishing this
arrhythmia and this effect is associated with decreased
norepinephrine levels.
(J Am Coli Cardiol1986;8:11-7)
reproducible disorder occurring primarily in young to mid-
dle-aged men without significant coronary artery disease,
who have minimal or no ventricular dysfunction and gen-
erally have a good prognosis. It has been assumed that in
this group elevated plasma catecholamine levels playa ma-
jor role in the pathogenesis of this disorder and that beta-
adrenergic blockade provides effective symptomatic relief.
Therefore, the aim of this study was to prospectively eval-
uate the relation of plasma catecholamines to the exercise-
related induction of ventricular tachycardia.
Methods
Study patients. Seventeen patients met the entrance cri-
teria (see later) and constituted the study group. All patients
signed informed written consent (protocol approved by the
Hahnemann Institutional Review Board on June 8, 1982).
The group consisted of normotensive subjects in whom all
antiarrhythmic, beta-adrenergic blocking and calcium chan-
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12 SOKOLOFF ET AL.
EXERCISE-INDUCED VENTRICULAR TACHYCARDIA
JACC Vol. 8, No. I
July 1986:11-7
nel blocking medication was discontinued at least 5 half-
lives before evaluation. Initially, all patients underwent a
minimum of 48 hours of ambulatory electrocardiographic
monitoring.
Exercise testing. The patients then underwent a post-
absorptive state (8 hour) maximal symptom-limited tread-
mill test in accordance with the Bruce protocol (1). They
were specifically instructed to avoid caffeine during the 8
hour period before testing. The exercise test was divided
into three phases: a 5 minute observation period, an exercise
period and a 10 minute recovery period. Patients were se-
lected for a control group matched for age and left ventric-
ular ejection fraction at rest (Group I) if they manifested
ventricular tachycardia (at least three consecutive ventricular
complexes, greater than 100/min) during ambulatory mon-
itoring and no ventricular tachycardia during the exercise
or recovery periods. Patients were initially selected for the
exercise-induced ventricular tachycardia group (Group 2) if
they had ventricular tachycardia during graded exercise or
recovery, or both. These patients were exercised again at
least 24 hours later and remained in Group 2 only if ven-
tricular tachycardia could be reproduced during the second
test. Patients who had ventricular tachycardia during both
ambulatory monitoring and exercise testing were excluded
from the study. Forms of ventricular ectopic activity other
than ventricular tachycardia were not considered. Ten pa-
tients were included in Group 2, and 7 patients were in-
cluded in Group I (the control group). One potential Group
2 patient with exercise-induced ventricular tachycardia was
excluded because of nonreproducibility.
Clinical evaluation. All patients had first pass radio-
nuclide angiography at rest and two-dimensional echocardi-
ography (to exclude mitral valve prolapse) as part of their
evaluation. Coronary artery disease was considered present
if there was an electrocardiographically documented myo-
cardial infarction (two Group 2 patients, two Group I pa-
tients) or if coronary angiography demonstrated at least 50%
luminal narrowing of the left main coronary artery or a
minimum of 70% narrowing of at least one major coronary
artery (two Group 2 patients, one Group I patient).
Thallium-20i imaging was performed in conjunction with
the exercise test for all Group I patients and was performed
with the second exercise test for all Group 2 patients.
Electrocardiographic leads V3, Vs and aVF were monitored
continuously during exercise testing. A 6 second delay cir-
cuit allowed recall of electrocardiographic events before the
occurrence of ventricular tachycardia. Exercise end points
were severe chest pain, dyspnea, fatigue, lightheadedness
or 2 mm or more of horizontal or downsloping ST segment
depression relative to baseline. Ventricular ectopic activity
of any form, including ventricular tachycardia, was not cause
for exercise termination unless it was associated with sig-
nificant symptoms.
in addition, a two channel Holter ambulatory electro-
cardiographic recording (modified leads VI and Vs) was
obtained for at least 15 minutes before exercise, during
exercise and for at least I hour after exercise. Blood pressure
was determined by arm cuff sphygmomanometry.
Exercise duration was measured and graded in minutes
according to the standard Bruce protocol, and other related
variables were measured in all patients at rest, peak exercise
and I, 2, 5 and 10 minutes into recovery. These measure-
ments were made with the patient standing, at rest, peak
exercise and I minute into recovery. The 2 and 5 minute
recovery measurements were made in the sitting position
and the 10 minute measurement was made in the supine
position. The variables evaluated included sinus rate, the
QTc interval measured from the surface electrocardiogram
and calculated using Bazett's formula (2) (measured QT
interval in seconds divided by the square root of the RR
interval in seconds) and the presence of a ventricular tachy-
cardia event. A ventricular tachycardia event was recorded
as having occurred at the closest measurement interval (peak
exercise, I, 2, 5 or 10 minutes into recovery). Tachycardia
during exercise or within 30 seconds of cessation of exercise
was recorded as having occurred at peak exercise. Tachy-
cardia occurring 30 to 90 seconds after cessation of exercise
was recorded as having occurred at I minute into recovery.
Samples for plasma catecholamine levels were obtained from
an indwelling 18 gauge antecubital vein catheter at each of
the measurement intervals.
At peak exercise, 2 mCi of thallium-20i was injected
through the intravenous catheter. The patient continued to
exercise for 30 to 60 seconds (during which time the sample
for peak exercise plasma catecholamine level was obtained).
Ten minutes after peak exercise, thallium images were ob-
tained in three projections. In all patients delayed imaging
was performed at 4 hours after exercise. The technique of
thallium imaging and the interpretation of results have been
described previously (3).
Repeat exercise after propranolol. All Group 2 patients
agreed to have exercise testing repeated after maximal in-
travenous beta-adrenergic blockade. Immediately before ex-
ercise, propranolol (0.2 mg/kg body weight) in solution with
50 cc of 5% dextrose in water was administered at a rate
of I to 2 mg/min with continuous electrocardiographic mon-
itoring. The standardized isoproterenol sensitivity test de-
scribed by Cleaveland et al. (4) was employed to assess the
degree of beta-adrenergic blockade, and in each patient this
was found to be maximal. The patient was then reexercised
using an identical protocol. If the patient's initial exercise
thallium study had revealed a defect interpreted as ischemia,
thallium imaging in conjunction with exercise was repeated.
Catecholamine assay. Blood (10 ml) obtained at each
of the prescribed measurement intervals was analyzed for
catecholamine concentration using a high performance Iiq-
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AMVT = ventricular tachycardia on ambulatory electrocardiographic
monitoring; CAD = coronary artery disease ; CM = cardiomyopathy;
EXVT == exercise-induced ventricular tachycardia ; F = female ; LVEF
= left ventricular ejection fraction; M = male; None = no organic heart
disease.
Table 1. Study Patientsuidchromatographic/electrochemical detection method adap-
ted from Mayer and Shoup (5). This method has been dem-
onstrated to be faster than and as accurate as the more
traditional radioenzymatic method (6-8). Catecholamines
were extracted from I ml plasma aliquots with activated
alumina and recovery efficiency was assessed with 3,4-
dihydroxybenzylamine as the internal standard.
Quality control studies reveal an interday coefficient of
variation of 3.2% and an intraday coefficient of 10.4% for
norepinephrine and respective values of 6.2 and 10.7% for
epinephrine. Limits of detection of norepinephrine and epi-
nephrine are 60 and 30 pg/ml, respectively, with a signal
to noise ratio equal to five.
Because of the fragile nature of the samples a rigid pro-
tocol of collection, handling and storage was employed.
Visibly hemolyzed samples were discarded. Plasma samples
were collected in B-D green top Vacutainer tubes containing
sodium heparin, a chelator (ethylene glycol-bis[beta-ami-
noethyl ether]-N ,N'-tetraacetic acid) and an antioxidant glu-
tathione with pH adjusted to 7.0, all of which add to cate-
cholamine stability during storage (- 80°C).
Statistical analysis. Intergroup differences were com-
pared using analysis of variance techniques. Intragroup var-
iances were compared using a repetitive measures analysis
of variance. In all analysis of norepinephrine levels a log-
arithmic transformation was done to normalize variance. In
all cases a probability (p) value of 0.05 or less was consid-
ered significant. All results are expressed as the mean ±
SEM or as the mean and the range .
Patient Age (yr) & Sex
AMVT (Group I)
I 38M
i 53F
3 55F
4 44F
5 37M
6 53F
7 68F
Mean 49.7
± SEM 4.1
EXVT (Group 2)
8 59F
9 69M
10 40M
II 58M
12 36F
13 67M
14 62F
15 37M
16 59F
17 25M
Mean 51.2
± SEM 4.8
Cardiac
Disease
None
CAD
CAD
None
None
CAD
CM
CM
None
CAD
CAD
None
CAD
CM
None
CAD
CM
Rest LVEF
(0/0 )
60
44
45
58
60
44
46
51.0
2.9
48
68
56
61
62
33
44
45
45
37
50.9
3.6
Results
The demographic characteristics of the two groups were
similar (Table I). Three patients in each group had no evi-
dence of organic heart disease. The remaining patients had
either no or mild to moderate impairment of left ventricular
function at rest.
Exercise testing results (Table 2). There was no dif-
ference between the two groups in exercise heart rate (Fig.
I) or exercise duration. All 17 patients exercised to fatigue;
none had chest pain or other symptoms requiring termination
of the test. Systolic blood pressure did not decrease in any
patient, and no patient had a decrease in diastolic pressure
of more than 10 mm Hg.
Four Group 2 patients had ventricular tachycardia at
peak exercise, five had ventricular tachycardia during the
recovery period and one had ventricular tachycardia during
both exercise and recovery . There was no correlation be-
tween the occurrence of a ventricular tachycardia episode
and any clinical or exercise characteristic . The ventricular
tachycardia in each patient was of constant rate and uniform
configuration; all had a left bundle branch configuration with
a normal or right axis. The episodes appeared as bursts
separated by at least one sinus complex and each began with
a late coupled ventricular complex (greater than 50% of the
preceding RR interval). The ventricular tachycardia rate
ranged from 140 to 160 beats/min (mean 154) with less than
10% rate variation in an individual patient. The duration of
ventricular tachycardia episodes ranged from three com-
plexes to self-terminating long runs (more than 30 com-
plexes) (Fig. 2). All ventricular tachycardia episodes were
well tolerated by the patients, and at no time was medical
intervention necessary .
The QTc intervals at rest did not differ between the two
groups. The maximal QTc change was defined at peak ex-
ercise in Group I and just before the onset of ventricular
tachycardia in Group 2. There was no correlation between
change in QTc interval and occurrence of ventricular tachy-
cardia.
The results of thallium imaging are presented in Table
2. Myocardial ischemia was detectable in 2 (20%) of 10
Group 2 patients and I (14%) of 7 Group I patients.
Catecholamine results (Table 3). Both norepinephrine
and epinephrine levels were measured. Epinephrine levels
are not reported because they were found to be at the lower
limit of detection where the assay is relatively imprecise
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Table 2. Exercise Test Results
Exercise QTc First Longest
Duration Rest/Change Thallium Occurrence Episode
Patient (min) (s) Result of VT ofVT
AMVT (Group I)
I 8.1 0.441D Normal
2 9.0 0.391D Scar
3 7.7 0.391D Ischemia
4 17.0 0.30/D Normal
5 10.6 0.40/D Normal
6 6.6 0.48/D Scar
7 8.0 0.42/D Normal
Mean 9.6 0.41
± SEM 1.3 0.02
EXVT (Group 2): Baseline
8 7.7 0.42/N Normal + I min 19S
9 9.2 O.4l1D Normal + 2 min 5C
10 9.0 O.4I/D Ischemia Peak 16C
11 10.0 0.42/D Scar + I min 7C
12 14.3 0.441D Normal + 5 min 155S
13 6.0 0.39/1 Scar Peak 8C
14 5.0 0.451D Normal Peak 3C
15 10.0 0.39/D Normal Peak 19C
16 4.4 0.32/1 Ischemia + I min 37C
17 14.0 0.50/D Scar Peak 5C
Mean 9.0 0.41
± SEM l.l 0.01
EXVT (Group 2): Beta-blockade
8 9.0 0.39/D None
9 9.9 0.40/D Peak 5C
10 9.5 0.40/D Normal None
11 12.2 0.36/1 None
12 12.5 0.36/N None
13 6.0 0.37/1 None
14 6.2 0.39/D None
15 10.1 0.4011 None
16 3.9 0.441D Normal None
17 14.0 0.4 liD None
Mean 9.3 0.39
± SEM 1.0 0.01
C = complexes; D = decrease; I = increase; N = no change; S = seconds; VT = ventricular tachycardia;
other abbreviations as in Table I.
(9). Norepinephrine levels (Fig. 3) were well above the limit
of detection and closely paralleled the level of exercise.
Peak norepinephrine levels occurred either at peak exercise
(1 of 10 in Group 2, I of 7 in Group 1) or at 1 minute into
recovery (9 of 10 in Group 2, 6 of 7 in Group 1).
There was no difference in plasma norepinephrine levels
between the groups. In addition, there was no correlation
between the onset of ventricular tachycardia and plasma
norepinephrine levels.
Effect of beta-blockade. Repeat testing of Group 2 pa-
tients after maximal intravenous beta-adrenergic blockade
with propranolol was performed 24 hours to 2 weeks sub-
sequent to the previous test. Heart rate (p < 0.0001) (Fig.
1) and plasma norepinephrine levels (p < 0.0002) (Table
3, Fig. 3 and 4) were reduced after beta-blockade. There
was no significant change in QTc interval at rest or in ex-
ercise duration, and ventricular tachycardia only occurred
in I of 10 patients after beta blockade.
Discussion
This study demonstrates that plasma norepinephrine lev-
els do not differentiate patients with exercise-induced ven-
tricular tachycardia from otherwise comparable patients in
whom ventricular tachycardia occurs only during routine
ambulatory monitoring. Nonetheless, propranolol does pre-
JACC Vol. 8, No.
JUly 1986:11-7
SOKOLOFF ET AL.
EXERCISE-INDUCED VENTRICULAR TACHYCARDIA
15
180
" "" :~.
. ....... .
...
.
. .. . j .... START
NE
pg/ml
456 .~>: .: . ::
.............. .. .... .;.. ...
. ... ... ... .. ..
........ :. ..
...-.. .. ........ .:
:/~ .
,
,
,
,
,
f/
GO -'j-- - -,-- - -,-- ---r- --,,-- -,.-
o 2
ART
ATE
ERVAL
Figure 1. Heart rate during exercise testing. Mean sinus rate
(ordinate) is plotted against time during the exercise protocol
(abscissa). Intervals0 through5 correspond, respectively, to rest,
peak exercise and 1, 2, 5 and 10 minutes' recovery. The solid
line represents Group 1 (the control group), the dash-dot line
represents Group2 (theexperimental group)duringbaselinetesting
and the dashed line represents Group 2 during testing after max-
imal beta-adrenergic blockade. SEM is indicated for each group
at each interval. There is no difference in sinus rate between the
two groups during the baseline exercise protocol. There is a sig-
nificant decrease (p < 0.000l) in sinus rate in Group 2 after beta-
blockade.
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vent exercise-induced ventricular tachycardia, although its
mechanism of action is not clear.
Possible mechanisms. High concentrations of the cate-
cholamine isoproterenol are known to induce or facilitate
electrical induction of ventricular tachycardia in susceptible
individuals in the electrophysiology laboratory (10-12). In
the study by Sung et al. (10), in a heterogeneous population,
a significant percent of what was termed exercise-induced
ventricular tachycardia was reproducible in the electro-
physiology laboratory only with infusion of catecholamine
and not with programmed stimulation, suggesting a mech-
anistic link between exercise-induced ventricular tachycar-
dia and catecholamines,
Although it was not the intent of this study to investigate
the exact mechanisms producing exercise-induced ventric-
ular tachycardia, we noted that most of our Group 2 patients
manifested several characteristics of exercise-related ven-
tricular tachycardia described by Wu et al. (13), such as a
rapid succession of tachycardia episodes separated by at
least one sinus complex, tachycardia rate in the range of
I60/min , gradual resumption of sinus rhythm with a de-
crease in frequency and length of the episodes and preven-
tion of the arrhythmia by beta-adrenergic blockade. Wu et
al. postulated that "triggered activity" may be the under-
lying mechanism responsible for the arrhythmia. Cranefield
(14) reported that norepinephrine increases the amplitude
of afterdepolarizations or causes their appearance in vitro,
a prerequisite for' 'triggered activity. " In addition, Arnsdorf
(15) found that beta-adrenergic blockade has a direct sup-
pressive effect on such activity.
Figure 2. Exercise-induced ventricular tachycardia (Group 2).
Continuous electrocardiographic recording(modified lead VI) dur-
ing baselineexercisetesting. The arrows denote the start and peak
of exercise. Plasma norepinephrine (NE) levels are shown on the
left and correspond to discrete points in the exercise protocol
shown on the right. A norepinephrine value is not available for
peakexercise. Episodesof self-terminating ventriculartachycardia
occur between 1 and 9 minutes of the recovery period.
It has been suggested (16) that peripheral plasma nor-
epinephrine levels continue to increase for several minutes
after the cessation of exercise and that this might be the
cause of life-threatening ventricular tachyarrhythmias.
However, this discrepancy between peak exercise and peak
Table 3. Mean Plasma Norepinephrine Levels (pg/ml)
Peak
Recovery (min)
Rest Exercise +1 +2 +5 +10
AMVT (Group I)
Mean 298 2,054 1,885 1,368 839 744
± SEM 30 302 243 130 70 117
n 7 7 7 7 7 7
EXVT (Group 2): Baseline
Mean 287 1,812 2,033 1,453 816 537
± SEM 30 179 184 128 77 96
n 10 9 10 10 10 9
EXVT (Group 2): Beta-Blockade
Mean 235 1,370 1,227 1,014 743 527
± SEM 35 151 157 113 113 79
n 10 9 9 10 10 10
n = number; other abbreviations as in Table I.
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Figure 3. Mean plasma norepinephrine levels during exercise
testing. Comparison of the logarithmic (LOG) transformation of
mean plasma norepinephrine (NE) levels for Group I (the control
group) (solid line), Group 2 (the experimental group)duringbase-
line testing (dash-dot line) and Group 2 after maximal beta-block-
ade (dashed line). SEM is indicatedfor eachgroupat each interval
of the exercise protocol as in Figure I. There is no difference in
norepinephrine levels throughout the protocol between Group I
and baseline Group 2; however, after maximal beta-adrenergic
blockade, norepinephrine levels in Group 2 are significantly de-
creased (p < 0.0(02).
norepinephrine levels is not surprising, because the majority
of plasma norepinephrine is derived from nerve synapses,
and there may be a lag time between what occurs at the
synaptic level and what is detected peripherally. In our
study, norepinephrine levels were maximal within I minute
after peak exercise.
Effect of beta-blockade. The decrease in plasma nor-
epinephrine levels after beta-adrenergic blockade with pro-
pranolol (Table 3, Fig. 3 and 4) has not been previously
reported. We are not aware of a study employing similarly
large doses of intravenous propranolol in patients. Sheehan
et al. (17), utilizing oral doses that achieved plasma levels
thought to be associated with effective beta-blockade in
normal subjects during exercise, reported that propranolol
blocks the action of norepinephrine at receptor sites but does
not affect norepinephrine release. However, oral propran-
olol has significant first pass hepatic clearance (18) and large
intravenous doses would be expected to result in substan-
tially higher plasma levels. As it is unlikely that higher
plasma propranolol levels would increase norepinephrine
clearance, it appears that norepinephrine secretion is di-
minished. Because, in our study, exercise duration did not
change after acute propranolol administration, this would
not account for decreased norepinephrine secretion; and the
postpropranolol abolition of previously reproducible ven-
tricular tachycardia is further evidence that exercise-induced
ventricular tachycardia is catecholamine mediated.
Previous studies. Woelfel et al. (19) also found that
large doses of propranolol, administered orally (the degree
of beta-blockade determined by peak sinus rate achieved
Figure 4. Exercise testingafterbeta-adrenergic blockade.Electro-
cardiographic records from the same patient as in Figure 2 after
maximal beta-adrenergic blockade are shown with identical for-
mat. No episodes of ventricular tachycardia occur despite similar
exercise duration.
during maximal exercise), were often required to prevent
exercise induction of previously reproducible ventricular
tachycardia; however, catecholamine levels were not re-
ported. Our findings suggest that this effect of propranolol
may be the result of decreased norepinephrine levels, re-
ceptor site blockade or a combination of the two,
Although our data are inferential they suggest that either
plasma norepinephrine is not related to exercise-induced
ventricular tachycardia or that these patients may be more
sensitive to normal levels of norepinephrine released during
maximal treadmill exercise testing. The latter concept is
supported by the excellent response of the arrhythmia to
beta-adrenergic blockade with propranolol, the lack of de-
tectable plasma epinephrine in association with the arrhyth-
mia and the frequent induction in susceptible individuals of
ventricular tachycardia by catecholamine infusion.
Our experimental group (Group 2) is similar to patient
groups evaluated by other researchers (13,19) in age, degree
of left ventricular dysfunction (moderate to none), repro-
ducibility of the arrhythmia (high), arrhythmia configuration
and response to beta-adrenergic blockade (excellent). These
patients may represent a distinct clinical group in which
catecholamines are the predominant pathogenetic factor in
lACC Vol. 8, No. I
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exercise-induced ventricular tachycardia, although such a
clinical correlation has not been established.
In other studies (10,20,21) patients were generally older
and had more severe cardiac disease, evaluation was not
restricted to ventricular tachycardia (20) (as compared with
more generalized ventricular ectopic activity) and the re-
producibility of exercise induction of ventricular tachycardia
was not carefully controlled (10,21). Arrhythmia pathogen-
esis in these patients is not clear and is likely to be multi-
factorial.
Limitations. It is not possible, on the basis of our data,
to determine the exact mechanism by which propranolol
abolishes exercise-induced ventricular tachycardia. We did
not exercise the control group (Group 1) after maximal
intravenous beta-adrenergic blockade and are therefore lim-
ited in evaluating norepinephrine levels after beta-blockade
in the experimental group (Group 2). Also, to clarify pro-
pranolol's effect or effects it is necessary to separate its
postsynaptic beta-adrenergic blocking action from the ob-
served decrease in plasma norepinephrine levels. This might
be accomplished by the administration of an agent such as
reserpine which decreases plasma norepinephrine to patients
with proven exercise-induced ventricular tachycardia.
Conclusions. We have demonstrated that patients with
reproducible ventricular tachycardia that occurs exclusively
during exercise testing have plasma norepinephrine levels
similar to those of patients without this arrhythmia. Thus,
patients with exercise-induced ventricular tachycardia may
be more sensitive to plasma norepinephrine than are oth-
erwise comparable patients. In 9 of 10 patients with exer-
cise-induced ventricular tachycardia the arrhythmia was
abolished by maximal beta-blockade. This blockade was
associated with a decrease in plasma norepinephrine levels.
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